Introduction
Autologous stem cell transplantation (SCT) has been shown to be an effective therapy for patients with recurrent diffuse large B-cell lymphoma (DLBCL). 1 In recurrent follicular lymphoma, several Phase II studies suggest that salvage treatment followed by consolidation with autologous SCT can result in prolonged disease-free survival (DFS) 2 4 whereas conventional dose chemotherapy is likely to produce Case report A32-year-old female was diagnosed with t(14; 18)-positive follicular lymphoma grade 2 in 1998 on a gastric biopsy.
Bone marrow involvement was also documented at that time, thus it was concluded that she had a stage IV disease before the start of the therapy. Subsequently, she was treated with 6 cycles of CHOP and obtained a CR. She had a potential risk of relapse with/without transformation, and was expected that she would be eligible for autologous SCT at the time of relapse. SCH at the time of first CR would likely have a higher stem cell yield than that at the time of second CR. In addition, because her marrow was involved with disease at the time of presentation but was cleared after induction chemotherapy, it was felt that this might be the best opportunity to harvest high quality PBSC. PBSC were harvested for 2 days (referred as to D1 and D2) following mobilization by subcutaneous filgrastim injection for 3 consecutive days (300 g, 600 g, and 300 g Table   1 ), followed by subcutaneous G-CSF at a dose of 300 g for 9 consecutive days followed by 75 g for 1 day. The lower viability of cells was observed after the contents of all 5 bags were combined ( Table 1 ). The patient developed stomatitis (grade 3) and febrile neutropenia (grade 3) following PBSCT and had 4 day-long diarrhea (grade 3) from preconditioning, but she recovered by day 13. She achieved a granulocyte count 500/mm 3 on day 10 and self-supporting platelet count 20 10 3 /mm 3 on day 12. She was discharged from our hospital on day 21. Currently, she remains free from lymphoma and other complications for more than 3.5 years.
Discussion
We report here a patient with recurrent follicular lymphoma (grade 3) who was successfully treated with high-dose chemotherapy and autologous PBSCT. However, this potentially unusual treatment course raises several issues to discuss. It is still controversial whether patients with recurrent follicular lymphoma in second CR should be treated with high dose chemotherapy with SCT support. It has been
shown that high-dose chemotherapy with autologous PBSCT prolongs progression free survival and overall survival and should be considered especially in patients with short first CR after chemotherapy containing rituximab, 4,7 but the role of PBSCT has to be redefined when rituximab can be used for maintenance therapy after second CR. 6 Furthermore, it has been shown that in selected younger patients with a high-risk profile, a potentially curative allogeneic SCT with dose-reduced conditioning may be considered in relapsed disease. 8, 9 From these points of view, our patient was young (42 years old) at the time of PBSCT, therefore allogeneic SCT as consolidation therapy may have been an option because she had two siblings. However, she also had PBSC that had been and lymphocyte subsets has been analyzed by Liseth et al. 15 They showed that recovery of viable cells was significantly better in 5% DMSO than in 10% whereas the frequencies of several T lymphocyte subsets but not NK cells showed DM-SO-dependent differences. 15 Collectively, long-term cryopreservation for more than 10 years is possible and could be standard clinical practice. We suggest that a patient who is young and has a high risk of relapse should be harvested at first CR to prepare for autologous SCT at second CR. In conclusion, our experience confirms previous reports that PBSC cryopreserved for around 10 years are sufficient for stem cell rescue following high dose chemotherapy.
